Is the mesocortical dopaminergic system involved in Parkinson disease?
about
Executive dysfunction in Parkinson's disease and timing deficitsWhat can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?Differential effects of dopamine-directed treatments on cognitionClassification and Characteristics of Pain Associated with Parkinson's DiseaseRegulation of dopamine system responsivity and its adaptive and pathological response to stressSemantic processing deficits in patients with Parkinson's disease: degraded representation or defective retrieval?Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protectionNeuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound.A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes.The contribution of neuroimaging for the study of cognitive deficits in Parkinson's disease.Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease.Regional cerebral blood flow in patients with Parkinson's disease under chronic levodopa therapy: measurements during "on" and "off" response fluctuations.Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.Cognitive concomitants of dopamine system stimulation in parkinsonian patients.Defective concept formation in parkinsonians is independent from mental deteriorationPragmatic comprehension deficit in Parkinson's disease.Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease.Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.MALDI mass spectrometry imaging of 1-methyl-4-phenylpyridinium (MPP+) in mouse brain.Amine accumulation: a possible precursor of Lewy body formation in Parkinson's disease.Counterfactual cognitive deficit in persons with Parkinson's disease.Brain systems underlying susceptibility to helplessness and depression.Psychotic symptoms in Parkinson's disease: pathophysiology and management.Memory systems analyses of mnemonic disorders in aging and age-related diseases.Treatment of behavioural symptoms and dementia in Parkinson's disease.Parkinson's disease dementia: a neural networks perspective.CD24 expression does not affect dopamine neuronal survival in a mouse model of Parkinson's disease.Prefrontal D1 dopamine signaling is required for temporal control.The late positive potential, emotion and apathy in Parkinson's disease.Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells.Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention.The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review.Probing basal ganglia functions by saccade eye movements.Anhedonia in Parkinson's disease: a systematic review of the literature.Functional neuroimaging in Parkinson's disease.Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.Differential aspects of cognitive impairment in patients suffering from Parkinson's and Alzheimer's disease: a neuropsychological evaluation.Hypothalamic compensatory mechanisms in Parkinson's disease.Biochemistry of Parkinson's disease 28 years later: a critical review.
P2860
Q21090466-15A0E21B-7959-4F79-AAF8-9E036549CA4DQ26767268-4DDC52C5-71DA-4319-A99D-11A946C028E6Q26801298-02AE6FD9-06A5-4F5A-BB41-F7D6EF2A6A14Q28066313-FDCC7D64-97E5-4429-AB52-DA2291A36202Q28081107-48F020AB-038C-48F4-9087-B2DD8D3EAC40Q30498974-9F147074-9872-404D-ADD0-8F7A47E847BFQ30895929-C328E382-1B36-4088-BDC4-A6B258CC40FDQ31172552-F68D6EF1-8EAC-4FB6-A732-EB3E60CB1F54Q31871480-25A56367-3CD0-478A-9770-5B8899218960Q31919970-149D11B5-A7E8-4C36-AD37-990C4C0A9288Q33593378-7095C1A6-B55C-489E-B994-3301E4E511B8Q33619721-F3A213B6-1ED2-436C-9F4D-903342DFDC59Q33622814-6EBAB538-6275-46FF-8B29-71D395B99362Q33628446-D701D9A0-4CFC-4C3C-AF52-E6E30B8D757FQ33629294-06806813-AE2A-4461-A812-26294B7B8DF1Q33629400-B2EC452D-0BAF-4572-9E9D-213EA457398FQ33790219-F0ED5701-8774-4E01-BAF2-5DFD802A92D1Q33967306-606DC2D8-4AD6-4D8A-8CFB-4C5A3F73F9E0Q33985023-8A374214-56BE-4EE6-85AD-0098A8673EACQ35069025-697EEF39-02CE-43D4-BF2C-7A648BCADAA9Q35222898-EA12E42F-4E46-449B-B406-1DC29BB529AFQ35475386-E103ECBB-A415-41F3-BD48-13373C0DD34BQ35684600-57FCDF5F-A557-4546-8BF0-6C4982D978E0Q35779329-4A4AD470-2368-40CB-966B-9FD80BCBCF99Q35998652-5B516608-E1D3-4D90-B63A-5743A7E24E98Q36089350-E6DCA1B9-FF7E-4FE7-B105-C8C4C672A981Q36186763-BBFBA1AD-A18B-431E-9B7D-EB5D637FC01EQ36275740-86E80BFA-3766-4E9F-9236-B62916CC6053Q36483541-F0ABB99F-CB02-4F8A-B148-59AC4C930768Q36925932-B155852D-C53B-4084-AAFB-CF8408287638Q37320970-7D678EDF-CD9D-46F3-AE05-150A284ADE93Q37491183-64679C1F-CFB0-403D-B9E7-235CEEC181DEQ37841542-D4EC76C7-C521-40FB-997D-A04379CF5409Q37885421-FA076B10-8BB8-4215-BDCD-41943BD747D3Q37887678-1EED87E8-1055-421E-8261-CC2A0CF3D4F5Q38088371-7411A9D9-947D-45FA-AC8A-DD5D358410B1Q38111335-A5965E3C-A3F0-4B5F-BCE5-4953F5711D19Q38214419-2364A375-A2B3-4A18-BBF6-30D48767D594Q38214420-C3C574D5-2ECF-4304-A6B6-E91DC2A0ACD8Q38351038-EF94A062-A0F3-467A-8596-C8BAF6D49CB3
P2860
Is the mesocortical dopaminergic system involved in Parkinson disease?
description
1980 nî lūn-bûn
@nan
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
1980年论文
@zh
1980年论文
@zh-cn
name
Is the mesocortical dopaminergic system involved in Parkinson disease?
@en
Is the mesocortical dopaminergic system involved in Parkinson disease?
@nl
type
label
Is the mesocortical dopaminergic system involved in Parkinson disease?
@en
Is the mesocortical dopaminergic system involved in Parkinson disease?
@nl
prefLabel
Is the mesocortical dopaminergic system involved in Parkinson disease?
@en
Is the mesocortical dopaminergic system involved in Parkinson disease?
@nl
P356
P1433
P1476
Is the mesocortical dopaminergic system involved in Parkinson disease?
@en
P2093
Javoy-Agid F
P304
P356
10.1212/WNL.30.12.1326
P407
P50
P577
1980-12-01T00:00:00Z